EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development and stability evaluation of extemporaneously compounded nimodipine oral suspension

Adham Elshamy, Hasnaa Osama, Afsaneh Lavasanifar, Forugh Sanaee, Jiangnan Hu, Yifu Chu, Lingyun Chen, Sherif Hanafy Mahmoud

Journal of Pharmacy & Pharmaceutical Sciences · 13.11.2026 · 29

DOI: 10.3389/jpps.2026.17227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, online erschienen am 13.11.2026. Verfasst von Adham Elshamy und 7 weiteren Autor:innen. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating neurological emergency often complicated by delayed cerebral ischemia. While nimodipine remains the only approved pharmacological intervention proven to improve clinical outcomes in this population, significant pharmacokinetic variability and administration challenges in dysphagic patients severely compromise its consistent clinical efficacy.

Purpose

To formulate an extemporaneously compounded nimodipine oral suspension and to systematically evaluate its physicochemical stability and feeding tube compatibility.

Methods

A compounded nimodipine suspension was prepared in 1:1 ORA-Plus® and ORA-Sweet® vehicles and stored under refrigerated and room temperature conditions for 28 days. Chemical stability was quantified via high-performance liquid chromatography (HPLC). Physical stability was evaluated by measuring pH, particle size, sedimentation volume, zeta potential, and viscosity. Administration feasibility was tested using standard enteral feeding tubes.

Results

The compounded formulation maintained chemical stability (90%–110% recovery) for 3 weeks refrigerated and 4 weeks at room temperature. Compared to the crude dispersion prepared by crushing tablets in water, the compounded suspension demonstrated a more negative baseline zeta potential (−21.43 ± 1.89 mV vs. −8.42 ± 2.28 mV, p < 0.001) and higher sedimentation volume (0.99 ± 0.01 vs. 0.26 ± 0.04, p < 0.001), confirming enhanced homogeneity and dispersibility. Rheological analysis confirmed a shear-thinning profile ideal for enteral delivery. Furthermore, feeding tube administration yielded >98% drug recovery without occlusion.

Conclusion

The compounded nimodipine suspension in this study provides a feasible alternative for enteral nimodipine administration. Future studies are needed to evaluate the formulation’s bioavailability.

Zitieren

APA

Elshamy, A., Osama, H., Lavasanifar, A., Sanaee, F., Hu, J., Chu, Y., Chen, L., & Mahmoud, S. H. (2026). Development and stability evaluation of extemporaneously compounded nimodipine oral suspension. Journal of Pharmacy & Pharmaceutical Sciences, 29. https://doi.org/10.3389/jpps.2026.17227

Vancouver

Elshamy A, Osama H, Lavasanifar A, Sanaee F, Hu J, Chu Y, et al. Development and stability evaluation of extemporaneously compounded nimodipine oral suspension. Journal of Pharmacy & Pharmaceutical Sciences. 2026;29. doi:10.3389/jpps.2026.17227

BibTeX
@article{Elshamy2026,
  author = {Elshamy, Adham and Osama, Hasnaa and Lavasanifar, Afsaneh and Sanaee, Forugh and Hu, Jiangnan and Chu, Yifu and Chen, Lingyun and Mahmoud, Sherif Hanafy},
  title = {Development and stability evaluation of extemporaneously compounded nimodipine oral suspension},
  journal = {Journal of Pharmacy & Pharmaceutical Sciences},
  year = {2026},
  volume = {29},
  doi = {10.3389/jpps.2026.17227}
}
Kostenlos starten →